← The SEC Ephemeris: the whole map
Fidelity BioPharma Co. Ontralfy
In the graph: all 1 documents (2 pages).
- Application
- NDA 216190
- Ticker
- Fidelity BioPharma Co.
- Product
- Ontralfy
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- March 29, 2024
From FDA letters and SEC filings. Not investment or medical advice.